VEN-201

About Ventoux Biosciences

Ventoux Biosciences is a private, preclinical biotech firm developing novel therapies for immune-fibrotic diseases, with an initial focus on Dupuytren's disease and Spinal Cord Injury. Its lead program, VEN-201, emerged from an AI-driven discovery platform analyzing multi-omic data and represents a potential first disease-modifying pharmacologic therapy for Dupuytren's. The company is led by a team with deep expertise in biostatistics, fibrosis biology, and finance, and is currently advancing its pipeline through preclinical validation with a strong translational rationale. Ventoux operates as a pre-revenue entity, building a differentiated pipeline backed by robust intellectual property and patient insight.

About Ventoux Biosciences

Ventoux Biosciences is a private, preclinical biotech firm developing novel therapies for immune-fibrotic diseases, with an initial focus on Dupuytren's disease and Spinal Cord Injury. Its lead program, VEN-201, emerged from an AI-driven discovery platform analyzing multi-omic data and represents a potential first disease-modifying pharmacologic therapy for Dupuytren's. The company is led by a team with deep expertise in biostatistics, fibrosis biology, and finance, and is currently advancing its pipeline through preclinical validation with a strong translational rationale. Ventoux operates as a pre-revenue entity, building a differentiated pipeline backed by robust intellectual property and patient insight.

Therapeutic Areas